Login to Your Account



With $150M in the bank, Dalcor seeks phase III success with dalcetrapib

By Marie Powers
News Editor

Tuesday, April 19, 2016

Seeking to succeed where big pharma failed, start-up Dalcor Pharma UK Ltd. completed a $100 million series B round to put an exclamation point on the $50 million series A the company closed late in 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription